Present and future management of anti-neutrophil cytoplasmic antibody associated vasculitis: how therapy changed the prognosis

  • Massimo L’Andolina Ambulatorio di Reumatologia, Divisione di Medicina Interna, PO di Tropea (VV), Italy.
  • Giovanni Forte Specialista in Malattie dell’Apparato Digerente, Catanzaro, Italy.
  • Norma M. Marigliano Specialista in Farmacologia Clinica, Università degli Studi Magna Graecia, Catanzaro, Italy.
  • Salvatore Galasso Specialista in Fisiatria, Mendicino (CS), Italy.
  • Francesca Mazzei Specialista Territoriale in Geriatria, Catanzaro, Italy.
  • Domenico Galasso | domenico.galasso@libero.it Direttore Emerito di Medicina Interna, AO Pugliese Ciaccio, Catanzaro, Italy.

Abstract

Anti-neutrophil cytoplasmic antibody associated vasculitis is part of a multi-systemic idiopathic, small vessel pouci-immune vasculitis. Given the heterogeneous spectrum of the disease, and the need to update therapeutic protocols, the aim of this review was to evaluate clinical-diagnostic approaches. We examined statistical data available in the literature, in particular the 2010 review of St. Hamour et al. Management of Anca-associated Vasculitis, published in Therapeutics and Clinical Risk Management. Acute immunosuppressive therapy and long-term maintenance, with the use of prednisolone, have significantly changed the prognosis of this disease, particularly compared with the 1970s before the introductions of steroids and cyclophosphamide. New drugs such as rituximab, monoclonal antibodies and other modulating immune system molecules are entering clinical use, and experience will confirm whether or not therapeutic guidelines are appropriate. The current diagnostic tools, ranging from laboratory and autoimmune tests, chest X-ray, broncho-alveolar lavage to capillaroscopy, allow prompt diagnosis and early treatment through a first phase of induction-remission, and a second phase of maintenance. There are, however, recurrent and refractory forms of the disease that require long-term immunosuppression and further research into this is merited. These issues have continued to drive the search for safer and more effective modulation of the immune system using targeted immunotherapy. However, the treatment limitations of incomplete efficacy, infection, and cumulative toxicity persist. Modifications to traditional treatment protocols by the use of azathioprine or methotrexate rather than cyclophosphamide, and the introduction of newer agents, such as rituximab, have meant that outcomes have been maintained while toxicity has been reduced.

Downloads

Download data is not yet available.
Published
2013-03-04
Section
Reviews
Keywords:
vasculitis, Wegener’s disease, Churg-Strauss syndrome.
Statistics
Abstract views: 576

PDF: 343
HTML: 933
Share it

PlumX Metrics

PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

How to Cite
L’Andolina, M., Forte, G., Marigliano, N. M., Galasso, S., Mazzei, F., & Galasso, D. (2013). Present and future management of anti-neutrophil cytoplasmic antibody associated vasculitis: how therapy changed the prognosis. Italian Journal of Medicine, 7(1), 14-25. https://doi.org/10.4081/itjm.2013.14